Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (January 2023)
49 slides from Genprex's investor presentation, Jan 6, 2023
Slide 1: Pioneering Gene Therapies for Large Patient Populations
© Genprex’ PIONEERING GENE THERAPIES FOR LARGE PATIENT POPULATIONS NASDAQ: GNPX January 2023
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS ‘Statements contained inthis presentation regarding matters that are not historical facts are “forward-lookingstatements” within the meaning ofthe Private Securities Litigation Reform Actof 1995, Because such statements are subjectto risks and uncertainties, actual results
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Advancing novel gene therapies for large markets and unmet need, in cancer and diabetes, with world-class academic partners and an expanding pipeline ONCOLOGY DIABETES + Non-viral gene therapy platform «Two drug candidates addressing both Type 1 + Novel approach using systemic
Slide 4: Research and Development Pipeline
© Genprex RESEARCH AND DEVELOPMENT PIPELINE oR CANDIDATE oNcoLocy REQORSAY IMMUNOGENE THERAPY REQORSA" IMMUNOGENE THERAPY REQORSA" IMMUNOGENE THERAPY Acclaim-1 Acclaim-2 unorsc.osen vamousoncovoortancers E> FREGORSAT MMUNOGENE THERAPY Tae | _ REQORSA* IMMUNOGENE THERAPY. NSCLC _oNc-002 REQORSA + Tar
Slide 5: Oncology Program
Slide 6: Lung Cancer: Leading Cause of Cancer Deaths
LUNG CANCER: LEADING CAUSE OF CANCER DEATHS 2M $48.7B+ LUNG CANCER INCIDENCE - GLOBAL GLOBAL MARKET More than two million new cases per year worldwide’. Global marketiis projected to grow from $18.3 billion in 2018 to $48.7 billion by 20262. 236K 18.6% LUNG CANCER INCIDENCE - USA AVERAGE LUNG CANCER
Slide 7: Tumor Suppressor Genes Deleted During Cancer Development
TUMOR SUPPRESSOR GENES DELETED DURING CANCER DEVELOPMENT Tumor suppressor genes are deleted early during cancer development 80% of all non-small cell lung cancers express <a decreased amounts of TUSC2 tumor suppressor protein Loss or reduction of TUSC2 expression is associated bawh with significantl
Slide 8: Novel Platform to Treat Cancer
NOVEL PLATFORM TO TREAT CANCER NOVEL SYSTEMIC GENE THERAPY DELIVERY PLATFORM FOR CANCER GENES SYNERGIES Multiple tumor — au ‘Advanced approach suppressor genes using combination therapy CANCERS Multiple cancers Genprex Nasdaq: GNPX
Slide 9: Oncoprex Nanoparticle Delivery System
ONCOPREX® NANOPARTICLE DELIVERY SYSTEM CATIONIC LIPID NANOPARTICLE CARRIES DRUG TO TUMORS REQORSA® IMMUNOGENE THERAPY Tumor suppressor ‘gene protein Plasmid with, zi TUSC2 gene C 5] Next gen non-viral, positively-charged lipid nanoparticle (LNP) is systemically delivered Plasmid containing tumor sup
Slide 10: Selective Uptake of REQORSA
SELECTIVE UPTAKE OF REQORSA® PATIENT 1 (0.02 mg/kg) TIENT 2 (0.06 mg/kg) PRE-TREATMENT BIOPSIES In all images, blue stain shows cell nuclei and red stain shows TUSC2 protein POST-TREATMENT BIOPSIES Nasdaq:GNPX 10
Slide 11: REQORSA Targets Cancer at Its Core
REQORSA TARGETS CANCER AT ITS CORE MULTIPLE ANTI-CANCER MECHANISMS OF ACTION \ ! y\ XX ! pi 2 CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS = MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases, Leads to programmed cancer cell death Promotes immune activity against cancer cell prolifer
Slide 12: AACR 21: REQORSA + Tagrisso Reduce Tumor Growth in Tagrisso-Resistant Tumors
AACR 21: REQORSA + TAGRISSO REDUCE TUMOR GROWTH IN TAGRISSO-RESISTANT TUMORS L hee i : t + + Osimertinib+TUSC2 combination on Osimertinib+TUSC2 combination on HI975-08iR tumors in NSG mice erties SCS comblinnti 20 i 1 Eto E § 2 3 00 8 3 an 5 renner: |G . ramneun es ° ° OH Of of o@ of of Of Dit ois o
Slide 13: General Study Characteristics (Acclaim-1)
GENERAL STUDY CHARACTERISTICS «FDA Fast Track Designation ‘i + Patients with advanced, EGFR mutant NSCLC whose disease progressed after Tagrisso Ac Cc ain 2 faa » 52005. ses + +158 patients Phase 1 Dose Escalation: -9-18 patients - Doses 1 & 2 Enrolled REQORSA in combination with AstraZeneca’s Tagri
Slide 14: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER ‘Survival on Lung Metastasis Mode! =o Tuscarporscriaa os 16 Ze 3 pays TUSC2+anti-PD1 exhibit greater antitumor activity than SE altialone Sen ona cgreyprotorsed either agent alon
Slide 15: REQORSA Modulates the Immune System
REQORSA MODULATES THE IMMUNE SYSTEM REQORSA IS SYNERGISTIC WITH ANTI-PD11 IN A HUMANIZED MOUSE MODEL OF LUNG CANCER i REQORSA + Keytruda ata te . ose r oe ; zr The independent immunologic effects of REQORSA and i, keytruda create synergy by adding increased immunologic i attack onthe tumor to PO-! i
Slide 16: AACR 21: REQORSA May Enhance First-Line Standard of Care
AACR 21: REQORSA MAY ENHANCE FIRST-LINE STANDARD OF CARE REQORSA + Keytruda + Chemo + REQORSA enhances the efficacy of chemo-immunotherapy on KL-mutant lung metastases in humanized mice. + Triple combination demonstrated strong antitumor efficacy and induced robust antitumor immunity in KRAS-LKB1 (K
Slide 17: General Study Characteristics (Acclaim-2)
GENERAL STUDY CHARACTERISTICS ‘| il ilfe «FDA Fast Track Designation > Patients with advanced NSCLC whose disease progressed after treatment with Keyeruda A im - . Sous anes . ~156 patients Phase 1: Up to 30 patients REQORSA in combination with Merck & Co's Keytruda for NSCLC Phase 2: 126 patients +
Slide 18: REQORSA in Small Cell Lung Cancer
REQORSA IN SMALL CELL LUNG CANCER Targeting Small Cell Lung Cancer in addition to NSCLO) allows Genprex to address virtually the entire lung cancer market. Small Cell Lung Cancer: + Consistently has low TUSC2 protein levels + Documented to often have deletion of one TUSC2 gene allele + Extensive sta
Slide 19: General Study Characteristics (Acclaim-3)
GENERAL STUDY CHARACTERISTICS = Patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy + ~10US.sites + ~62 patients REQORSA in combination with Genentech, Inc's Tecentriq for SCLC Phase 1: Up to 12 patients Phase 2: ~50 patients «Expect to dose First P
Slide 20: Diabetes Program
DIABETES PROGRAM
Slide 21: Novel Gene Therapy Diabetes Program
NOVEL GENE THERAPY DIABETES PROGRAM COLLABORATION WITH UNIVERSITY OF PITTSBURGH INTENDED TO ADDRESS ENTIRE DIABETES MARKET 37.3M or 11.3% of Americans Have Diabetes' Type 1 Diabetes: An auto-Immune Type 2 Diabetes: Inability of the condition where the body's immune 90-95% Pancreas to produce enough
Slide 22: Diabetes: A Global Epidemic
DIABETES: A GLOBAL EPIDEMIC 537M S966B DIABETES PREVELANCE - GLOBAL* EST ANNUAL GLOBAL DIABETES EXPENDITURES Expected to rise to 643M by 2030 and 783M by 2045. 316% increase in global healthcare expenditures since 20062. $4158 expenditures (43%) associated w/ US and Caribbean. 37.3M 24B DIABETES PRE
Slide 23: Diabetes Causes Serious Complications
DIABETES CAUSES SERIOUS COMPLICATIONS HEART DISEASE Leading cause of death for men and women in U.S. Diabetics are 2x.as likely to have heart disease or a stroke. CHRONIC KIDNEY DISEASE (CKD) Approximately 1 in 3 adults with diabetes have CKD. Kidney diseases are the 9" leading cause of death in U.S
Slide 24: Diabetic Patients in Need of Advanced Therapy
DIABETIC PATIENTS IN NEED OF ADVANCED THERAPY POTENTIAL FOR DISEASE MODIFCATION FOR LONG-TERM EFFECTIVENESS 1889 1922 Gplacoenben a + Despite certain advancements in compromised for many with diabetes. + Diabetes gene therapies hold potential to provide long-term effectiveness or change the course o
Slide 25: GPX-002 Replenishes Levels of Insulin
GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTIONIN T1D AAV vector with a glucagon promoter to deliver the Novel infusion process uses an endoscope and an Pdx1 + MafA(PM) genes to the pancreas. Transforms alpha cells in the pancreas into functional beta-like cells, which ca
Slide 26: Reversed Drug-Induced Diabetes in T1D Mouse Model
Blood glucose (mg/dl) REVERSED DRUG-INDUCED DIABETES IN T1D MOUSE MODEL alloxan AAV-8 injection GFP = Green Fluorescent Protein fluorescent marker) PM =Pdel + Mat 1020, beta cell mass (mo) to Beta Cll, Induced by Virol Gene Theropy, Reverses Autoimmune + =a Untreated — aigxan+ __alloxan+ Control aav
Slide 27: Restored Blood Glucose in T1D Mouse Model for Four Months
RESTORED BLOOD GLUCOSE IN T1D MOUSE MODEL FOR FOUR MONTHS B10 od ; | i - } | e a é i cue g oa | } Eos Pas a / a i NOD NOD AAV-GFP AAV-PM @ 10 12 1 16 18 20 22 24 26 ‘Time (wees) + Oneweek ina mouse tends to correlate to about one year in humans. + The average age of onset in Non-Obese Diabetic (NOD)
Slide 28: Induced Generation of Functional Insulin Expressing Cells from Alpha Cells in Human Islets
INDUCED GENERATION OF FUNCTIONAL INSULIN EXPRESSING cc] Blood glucose (mg/dl) CELLS FROM ALPHA CELLS IN HUMAN ISLETS G10 GFP= Green 2 Fluorescent Protein 2 ‘ae fluorescent marker g PM = Paixl + MafA 8 = g 05 © Time (day) 8 & 5 ol ‘ALX islet transplantation Analysis SIZAAVGRE SIAR Human islets treate
Slide 29: NN Ll | = bad li
NN Ll | = 1 bad li
Slide 30: GPX-003 Rejuvenates and Replenishes Beta Cells
GPX-003 REJUVENATES AND REPLENISHES BETA CELLS USES INSULIN PROMOTER TO ADDRESS T2D T2D stresses beta cells and their insulin production. + GPX-003 is designed to replenish and rejuvenate beta cells and insulin production. + Uses an endoscope and an AAV vector to deliver the Pdx1 + MafA(PM) genes to
Slide 31: Manufacturing
Slide 32: Investment in Manufacturing Mitigates Risk
INVESTMENT IN MANUFACTURING MITIGATES RISK EXCEPTIONAL CMC EXPERTISE & INTEGRATED CDMO NETWORK 50+ Years Combined Team Experience Customized CMC Strategy for Accelerated Development Core Competencies and Competitive Advantages Risk Assessment & Remediation for Successful FDA BLA Submission Building
Slide 33: Plasmid DNA Manufacturing for Oncology
PLASMID DNA MANUFACTURING FOR ONCOLOGY CONSISTENT DRUG SUBSTANCE WITH GMP PROCESS SCALE-UP AND SCALE-OUT frm, R pon 4 Ph 1/Ph 2/ Ph 2b g Loar Post. Commercialization Commercial Readiness Sal ‘and Harvest E Coli Master |) ememadon Bank Pepatarsen) (qrnneps cet |( “sdictgue” | eamacerepty Lysis Sep.,
Slide 34: Oncoprex Non-Viral LNP Manufacturing
ONCOPREX® NON-VIRAL LNP MANUFACTURING COMPANY EXPERTISE ENABLES HIGHEST QUALITY LNP DRUG PRODUCTS Phy Ph 1/Ph 2/ Ph 2b Commercial Readiness Sterile Filtration Tangential Flow Filtration Lipid Selection Ficfor-purpose > lipid formulation J —_ Self-assembly of nanoparticles with defined sizeand proper
Slide 35: AAV Manufacturing Overview for Diabetes
AAV MANUFACTURING OVERVIEW FOR DIABETES CMC STRATEGY FOR RISK REDUCTION, EFFICIENCY, ACCELERATED DEVELOPMENT No major CMC changes anticipated from Scalable to support Scale-up & Scale-out process commercialization globally design model using ‘Monte Carlo’ analysis Designed to reduce GMP Accelerated
Slide 36: Corporate
Slide 37: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD Chairman, President & Chief Executive Officer + 30+ years of expertise in corporate law, including, corporate governance, in biotech industry + Former owner of securities broker dealer firm RYAN CONFER, MS. Chief Financial Officer + 10+ years of C-L
Slide 38: Meet Our Team
a] 3 MEET OUR TEAM COMPANY MANAGEMENT THOMAS GALLAGHER, JD Senior Vice President, Intellectual Property and Licensing + 20+ years of expertise in biotech IP law, business development, licensing transactions + Seasoned|P executive and arrarney DAVID SCHLOSS, JD Senior Vice President, Human Resources
Slide 39: Meet Our Team: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD JACK A. ROTH MD, FACS, Chairman Professor and Bud Johnson Distinguished Clinical Chair, Department of Thoracic and Cardiovascular ‘Surgery: Chief, Section of Thoracic Molecular ‘Oncology: Professor of Molecular and Cellular Oncology; UT MD Anderson Cancer Cent
Slide 40: Meet Our Team: Clinical Advisory Board
MEET OUR TEAM CLINICAL ADVISORY BOARD. HORE wy OL GEORGE PeDPLES MD, MHS, FACP ye MD ines) + Professor of Meticine, Division of Medical Oncology ( + Chief Executive Officer of Cancerlnsight LLC, inthe Deparment of Surgery at Duke University wi boutique cancerimmunctherapy CRO + Research expertise in
Slide 41: Meet Our Team: Board of Directors
MEET OUR TEAM BOARD OF DIRECTORS RODNEY VARNER, JD Chairman of the Board + 30+ years of expertise in corporate law, including corporate governance, in biotech industry + Former owner of securities broker dealer firm JOSE A. MORENO TOSCANO Board Director + Chief Executive Officer, LFB USAlnc + 20+ ye
Slide 42: GNPX at a Glance
GNPX AT A GLANCE 30-DAY AVG SHARES COMPANY sympot | EXCHANGE | SHAREPRICE | MARKET CAP satel Peis Genprex,Inc. GNPX Nasdaq $173 33M 273K 48020324 $25.5 Million Alldata are as of January 5, 2023, except for shares outstanding and cash which are as of September30, 2022. Genprex Naseag:cnex 42
Slide 43: Achievements and Upcoming Milestones
ACHIEVEMENTS AND UPCOMING MILESTONES Acclaim -1 Acclaim -2 Acclaim 3 GPX-002 CORPORATE Approval to Advance into 3rd Cohort of Dose Escalation in Q4 2022 Complete Phase 1 Dose Escalation by end of Q1 2023 Present Phase 1 data at Scientific Meeting in Q2 2023 Complete Phase 1 portion of Acclaim-2 by e
Slide 44: We Believe 21st Century Gene Therapies
WE BELIEVE 21ST CENTURY GENE THERAPIES LARGE MARKETS AND UNMET NEED. IN A FUTURE OF COMBINATION TRIALS WITH TOP TRANSFORMATIONAL SELLING DRUGS TWO FDA FAST TRACK DESIGNATIONS PATIENT CARE EXPLORING NEW INDICATIONS AND PARTNERSHIPS Nasdaq:GNPX 44
Slide 45: Genprex Contact
oO Genprex’ NASDAQ: GNPX (877)774-GNPX | investors@genprex.com Nasdaq: GNPX
Slide 46: Appendix
©) Genprex APPENDIX
Slide 47: ONC-001 and ONC-002
ONC-001 AND ONC-002 REQORSA MONOTHERAPY AND REQORSA + TARCEVA COMBINATION DOSE ESCALATION STUDY (ONC-001) Favorable safety profil after being treated in more than 50 patients REQORSA + TARCEVA (ONC-002) Ph 2 data in subjects with or without EGFR mutations Pointe i20) Conte Rapa ome : ae) aes aaa 2 y
Slide 48: AAV Platform Upstream Manufacturing
AAV PLATFORM UPSTREAM MANUFACTURING DEBOTTLENECKING FOR OPERATIONAL EFFICIENCY Construct Plasmid Cell Culture Transfection Harvest Selection Engineering HEK293 Plasmid DNA Cellgrowh Pinal ap Plasmid DNA propagation the bloresctorto lysed from Chosen based nighly specific hasan HEKG23 cells on tropis
Slide 49: AAV Platform Downstream Manufacturing
AAV PLATFORM DOWNSTREAM MANUFACTURING ENABLES STATE OF CONTROL AND ROBUST GMP Separation (Concentration, ) (Quality Control} Drug Product) (Quality control) Labeling & Purification Final Filing Packaging Foren In-process In-process Filtration testing for Purified vectors testing for quality data fil